


08-31-06

Attorney's Docket No.: 17080-002002/601B



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : John R. McDonald et al.      Art Unit : 1647  
Serial No. : 09/360,242      Examiner : Robert S. Landsman  
Filed : July 22, 1999      Conf. No. : 3887  
Cust. No. : 20985      Notice of Allowance Date: August 8, 2006  
Title : METHODS AND COMPOSITIONS FOR TREATING SECONDARY  
TISSUE DAMAGE AND OTHER INFLAMMATORY CONDITIONS AND  
DISORDERS

**Mail Stop Issue Fee**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**


Dear Sir:

Transmitted herewith are an Issue Fee Transmittal Form PTOL-85 (1 page),  
Comments on Examiner's Reasons for Allowance, a check in the amount of \$742.00 for the  
Issue Fee and 14 advanced copies, and a return postcard for filing in connection with the  
above-identified application.



The Commissioner is hereby authorized to charge any fees that may be due in connection with  
this paper or with this application during its entire pendency to Deposit Account No. 06-1050.  
A duplicate of this sheet is enclosed.

Respectfully submitted,

  
Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 17080-002002/601B  
**Address all correspondence to:**  
Stephanie L. Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (202) 626-7796  
email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number **EV 740121964 US**  
Date of Deposit **August 29, 2006**  
I hereby certify that this paper is being deposited with the United  
States Postal "Express Mail Post Office to Addressee" Service  
under 37 CFR §1.10 on the date indicated above and is addressed  
to: Mail Stop Issue Fee, Commissioner for Patents, U.S. Patent and  
Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Stephanie Seidman



Attorney's Docket No.: 17080-002002/601B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :	John R. McDonald et al.	Art Unit :	1647
Serial No. :	09/360,242	Examiner :	Robert S. Landsman
Filed :	July 22, 1999	Confirmation No.:	3887
Cust. No. :	20985	Notice of Allowance Date:	August 8, 2006
Title :	METHODS AND COMPOSITIONS FOR TREATING SECONDARY TISSUE DAMAGE AND OTHER INFLAMMATORY CONDITIONS AND DISORDERS		

**MAIL STOP ISSUE FEE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**COMMENTS ON EXAMINER'S REASONS FOR ALLOWANCE**

Dear Sir:

Responsive to the Notice of Allowance mailed August 8, 2006, and to the Reasons for Allowance set forth in connection with the Notice of Allowance, mailed April 25, 2006, consideration of the following remarks is respectfully requested.

**REMARKS**

A check in the amount of \$742 for the Issue Fee for a small entity and an advance order of 14 copies of the issued patent accompanies this response. Any fees that may be due in connection with this paper or this application during its entire pendency may be charged to Deposit Account No. 06-1050. If a Petition for extension of time is needed, this paper is to be considered such Petition.

The Examiner states that "the claims are drawn to methods of targeting activated cells, which allow for more specific than previous cell-targeting methods." Applicant respectfully submits that there are several independent method claims allowed and that the methods target

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 740121964 US  
Date of Deposit August 29, 2006

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Mail Stop Issue Fee, Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Stephanie Seidman

Applicant : John R. McDonald et al.  
Serial No. : 09/360,242  
Filed : July 22, 1999

Attorney's Docket No.: 17080-002002/601B  
COMMENTS ON REASONS FOR ALLOWANCE

immune cells and immune effector cells that can be activated. The methods target cells that express receptors to which chemokine receptor targeting agents or portions thereof bind.

All responses of record are incorporated herein. Briefly, as discussed in the responses of record, targeting such receptors has not been taught or suggested in any art of record. The instant inventors, however, recognized that chemokines play an intimate role in varied diseases, and, as described in the application, provide a large repertoire of molecules that interact with an array of receptors. It is the instant inventors who have identified chemokine receptors as ideal targets for delivery of agents, such as toxins, to cells that participate in an underlying common response. Among the claimed methods are those for inhibiting proliferation, migration or activation of cells involved in such response. The conjugates provided in the application afford a way to treat of any disease in which inappropriate triggering, dysregulation or over-activation of the immune response is involved.

As discussed in the previous responses, claim 29 and dependents are directed to methods for treating pathological conditions by treating the underlying pathology associated with inflammatory responses and secondary tissue damage associated with activation, proliferation and migration of immune effector cells by inhibiting activation, proliferation or migration of immune effector cells. Claim 35 and dependents are directed to a methods of targeting agents to immune effector cells; claim 40 and dependents are directed to a methods of treating secondary tissue damage by inhibiting the proliferation, migration or physiological activity of the secondary tissue damage-promoting cells.; claim 72 and dependents are directed to methods of inhibiting proliferation, migration or activation of immune effector cells; and claim 86 and dependents are directed a methods of treating a disease or disorder associated with an inflammatory response by identifying immune cells that are activated in the disease or disorder and inhibiting proliferation, migration or activation of the immune cells.

None of the art of record, singly or in any combination thereof, teaches or suggests methods that exploit the chemokine system for targeting agents to cells, such as immune cells, including immune effector cells and other cells that can be activated, that express receptors to which chemokine receptor targeting agents or portions thereof interact to deliver the linked agent (or portion thereof) and effect internalization thereof.


\* \* \*

Applicant : John R. McDonald et al.  
Serial No. : 09/360,242  
Filed : July 22, 1999

Attorney's Docket No.: 17080-002002/601B  
COMMENTS ON REASONS FOR ALLOWANCE

Entry of the above remarks into the record of the application is respectfully requested.

Respectfully submitted,



---

Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 17080-002002/601B

**Address all correspondence to:**

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (202) 626-7796  
E-mail: seidman@fr.com